Compare Adecoagro SA (AGRO) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs BioNTech SE - ADR — how do they compare? Adecoagro SA trades at $9.24 (market cap $1.34B), while BioNTech SE - ADR trades at $93.16 (market cap $23.30B). The key difference: BioNTech SE - ADR is far larger — about 17.4× Adecoagro SA's market cap, and Adecoagro SA pays a 3.19% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AGRO | BNTX | |
|---|---|---|
Market Cap | $1.34B | $23.30B |
Sector | Technology | Health |
52-Week High | $15.25 | $119.34 |
52-Week Low | $7.13 | $83.89 |
Enterprise Value | $3.37B | $6.60B |
Dividend Yield | 3.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.29, down 3.83% today, with a bearish technical signal and mixed earnings performance. The company reported strong adjusted EBITDA growth in Q2 2026 ($172.5M) and is expanding via acquisition of the Caarapó mill. However, recent quarters show earnings misses against expectations, with net income margin at just 0.91% for 2026. Valuation metrics appear reasonable with P/S of 0.71 and P/B of 0.77, but high P/E of 522.78 reflects profitability challenges.
The outlook remains cautious with analyst consensus leaning toward Hold (50%) amid execution risks from recent acquisitions and commodity volatility. Positive catalysts include operational efficiency gains and expansion in South American markets, but investors face headwinds from elevated leverage and macroeconomic sensitivity to oil and gas prices.
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
